Progress in prion vaccines and immunotherapies

Expert Opinion on Biological Therapy

Volumn 5, Issue 1, 2005, Pages 97-110

  Griffin, Jennifer K ^a   Cashman, Neil R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6H4 ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3149; MONOCLONAL ANTIBODY 8B4; MONOCLONAL ANTIBODY 8H4; MONOCLONAL ANTIBODY D13; MONOCLONAL ANTIBODY D18; MONOCLONAL ANTIBODY E123; MONOCLONAL ANTIBODY ICSM 18; MONOCLONAL ANTIBODY ICSM 35; MONOCLONAL ANTIBODY R1; MONOCLONAL ANTIBODY R2; MONOCLONAL ANTIBODY R72; OLIGODEOXYNUCLEOTIDE; PEPTIDE; POLYCLONAL ANTIBODY; POLYPROTEIN; PRION PROTEIN; PRION PROTEIN ANTIBODY; PRION PROTEIN[118-137]; PRION PROTEIN[131-150]; PRION PROTEIN[151-170]; PRION PROTEIN[182-202]; PRION PROTEIN[211-230]; PRION PROTEIN[31-50]; PROTEIN ANTIBODY; PROTEIN DNAK; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRION DISEASE; PROTEIN FOLDING; REVIEW; TREATMENT OUTCOME;

ANIMALS; HUMANS; IMMUNOTHERAPY; PRION DISEASES; PRIONS; VACCINES;

EID: 12244310503     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.1.97     Document Type: Review

References (96)

1. COLLINGE J: Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. (2001) 24:519-550.
2. PRUSINER SB: Prions. Proc. Natl. Acad. Sci. USA (1998) 95:13363-13383.
3. PRUSINER SB: Novel proteinaceous infectious particles cause scrapie. Science (1982) 216:136-144.
4. BENDHEIM PE, BROWN HR, RUDELLI RD et al.: Nearly ubiquitous tissue distribution of the scrapie agent precursor protein. Neurology (1992) 42:149-156.
5. BOLTON DC, MCKINLEY MP, PRUSINER SB: Identification of a protein that purifies with the scrapie prion. Science (1982) 218:1309-1311.
6. DONNELLY CA, FERGUSON NM, GHANI AC, ANDERSON RM: Implications of BSE infection screening data for the scale of the British BSE epidemic and current European infection levels. Proc. R. Soc. Lond. B. Biol. Sci. (2002) 269:2179-2190.
7. WILESMITH JW, WELLS GA, CRANWELL MP, RYAN JB: Bovine spongiform encephalopathy: epidemiological studies. Vet. Rec. (1988) 123:638-644.
8. WILL RG, IRONSIDE JW, ZEIDLER M et al.: A new variant of Creutzfeldt-Jakob disease in the UK. Lancet (1996) 347:921-925.
9. BRUCE ME, WILL RG, IRONSIDE JW et al.: Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature (1997) 389:498-501.
10. HILL AF, DESBRUSLAIS M, JOINER S et al.: The same prion strain causes vCJD and BSE. Nature (1997) 389:48-50, 526.
11. LLEWELYN CA, HEWITT PE, KNIGHT RS et al.: Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion Lancet (2004) 363:417-421.
12. PEDEN AH, HEAD MW, RITCHIE DL et al.: Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous panent Lancet (2004) 364:527-529.
13. AUCOUTURIER P, CARP RI, CARNAUD C, WISNIEWSKI T: Prion diseases and the immune system. Clin. Immunol. (2000) 96:79-85.
14. PORTER DD, PORTER HG, COX NA: Failure to demonstrate a humoral immune response to scrapie infection in mice. J. Immunol. (1973) 111:1407-1410.
15. KINGSBURY DT, SMELTZER DA, GIBBS CJ, GAJDUSEK DC: Evidence for normal cell-mediated immunity in scrapie-infected mice. Infect. Immun. (1981) 32:1176-1180.
16. PRUSINER SB, GROTH D, SERBAN A, STAHL N, GABIZON R: Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies, Proc. Natl. Acad. Sci. USA (1993) 90:10608-10612.
17. WEISSMANN C, BUELER H, FISCHER M et al.: PrP-deficient mice are resistant to scrapie. Ann. NY Acad. Sci. (1994) 724:235-240.
18. BUELER H, AGUZZI A, SAILER A et al.: Mice devoid of PrP are resistant to scrapie. Cell (1993) 73:1339-1347.
19. ARBEL M, LAVIE V, SOLOMON B: Generation of antibodies against prion protein in wild-type mice via helix peptide immunization. J. Neuroimmunol. (2003) 144:38-45.
20. BAINBRIDGE J, JONES N, WALKER B: Multiple antigenic peptides facilitate generation of anti-prion antibodies. Clin. Exp. Immunol. (2004) 137:298-304.
21. KOLLER MF, GRAU T, CHRISTEN P: Induction of antibodies against murine full-length prion protein in wild-type mice. J. Neuroimmunol. 2002 132:113-116.
22. ROSSET MB, BALLERINI C, GREGOIRE S, METHAROM P, CARNAUD C, AUCOUTURIER P: Bteaking immune tolerance to the prion ptotein using prion protein peptides plus oligodeoxynucleotides-CpG in mice. J. Immunol. (2004) 172:5168-5174.
23. GREGOIRE S, LOGRE C, METHAROM P et al.: Identification of two immunogenic domains of the prion protein - PrP - which activate class II-restricted T cells and elicit antibody responses against the native molecule. J. Leukoc. Biol. (2004) 76:125-134.
24. EKLUND CM, KENNEDY RC, HADLOW WJ: Pathogenesis of scrapie virus infection in the mouse. J. Infect. Dis. (1967) 117:15-22.
25. FRASER H, DICKINSON AG: Pathogenesis of scrapie in the mouse: the role of the spleen. Nature (1970) 226:462-463.
26. ERASER H, DICKINSON AG: Studies of the lymphoreticular system in the pathogenesis of scrapie: The role of the spleen and thymus. J. Comp. Pathol. (1978) 88:563-573.
27. KIMBERLIN RH, WALKER CA: Pathogenesis of mouse scrapie: Dynamics of agent replication in spleen, spinal cord, and brain after injection by different routes. J. Comp. Pathol. (1979) 89:551-562.
28. VAN KEULEN LJ, SCHREUDER BE, MELOEN RH, MOOIJ-HARKES G, VROMANS ME, LANGEVELD JP: Immunohistochemical detection of prion protein in lymphoid tissues of sheep with natural scrapie. J. Clin. Microbiol. (1996) 34:1228-1231.
29. MCBRIDE PA, EIKELENBOOM P, KRAAL G, FRASER H, BRUCE ME: PrP protein is associated with follicular dendritic cells of spleens and lymph nodes in uninfected and scrapie-infected mice. J. Pathol. (1992) 168:413-418.
30. BROWN KL, RITCHIE DL, MCBRIDE PA, BRUCE ME: Detection of PrP in extraneutal tissues. Microsc. Res. Tech. (2000) 50:40-45.
31. HILL AF, ZEIDLER M, IRONSIDE JW, COLLINGE J: Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet (1997) 349:99-100.
32. HILTON DA, FATHERS E, EDWARDS P, IRONSIDE JW, ZAJICEK J: Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet (1998) 352:703-704.
33. OUTRAM GW DICKINSON AG, FRASER H: Developmental maturation of susceptibility to scrapie in mice. Nature (1973) 241:536-537.
34. OUTRAM GW DICKINSON AG, FRASER H: Reduced susceptibility to scrapie in mice after steroid administrarion. Nature (1974) 249:855-856.
35. DICKINSON AG, FRASER H, MCCONNELL I, OUTRAM GW Mitogenic stimulation of the host enhances susceptibility to scrapie. Nature (1978) 272:54-55.
36. FRASER H, FARQUHAR C: Ionising radiation has no influence on scrapie incubation period in mice. Vet. Microbiol. (1987) 13:211-223.
37. SETHI S, LIPFORD G, WAGNER H et al.: Postexposure prophylaxis against prion disease with a stimulator of innate immunity. Lancet (2002) 360:229-230.
38. HEIKENWALDER M, POLYMENIDOU M, JUNT T et al.: Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat. Med. (1994) 10:187-192.
39. RAEBER AJ, SAILER A, HEGYI I et al.: Ectopic expression of prion protein (PrP) in T lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion replication. Proc. Natl. Acad. Sci. USA (1999) 96:3987-3992.
40. O'ROURKE KI, HUFF TP, LEATHERS CW, ROBINSON MM, GORHAM JR: SCID mouse spleen does not support scrapie agent replication. J. Gen. Virol. (1994) 75:1511-1514.
41. LASMEZAS CI, CESBRON J-Y, DESLYS J-P et al.: Immune system-dependent and-independent replication of the scrapie agent. J Virol. (1996) 70:1292-1295.
42. BROWN KL, STEWART K, BRUCE ME, FRASER H: Severely combined immunodeficient (SCID) mice resist infection with bovine spongiform encephalopathy. J Gen. Virol. (1997) 78:2707-2710.
43. KLEIN MA, FRIGG R, FLECHSIG E et al.: A crucial role for B cells in neuroinvasive scrapie. Nature (1997) 390:687-690.
44. BROWN KL, STEWART K, RITCHIE DL et al.: Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nat. Med. (1999) 5:1308-1312.
45. RAEBER AJ, KLEIN MA, FRIGG R, FLECHSIG E, AGUZZI A, WEISSMANN C: PrP-dependent association of prions with splenic but not circulating lymphocytes of scrapie-infected mice. EMBO J. (1999) 18:2702-2706.
46. KITAMOTO T, MURAMOTO T, MOHRI S, DOH-URA K, TATEISHI J: Abnormal isoform of prion protein accumulates in follicular dendritic cells in mice with Creutzfeldt-Jakob disease. J. Virol (1991) 65:6292-6295.
47. MONTRASIO F, FRIGG R, GLATZEL M et al.: Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science (2000) 288:257-259.
48. MABBOTT NA, MACKAY F, MINNS F, BRUCE ME: Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie. Nat. Med. (2000) 6:719-720.
49. MABBOTT NA, YOUNG J, MCCONNELL I, BRUCE ME: Follicular dendritic cell dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway dramatically reduces scrapie susceptibility. J. Virol. (2003) 77:6845-6854.
50. MABBOTT NA, MCGOVERN G, JEFFREY M, BRUCE ME: Temporary blockade of the tumor necrosis factor receptor signaling pathway impedes the spread of scrapie to the brain. J Virol. (2002) 76:5131-5139.
51. MABBOTT NA, WILLIAMS A, FARQUHAR CF, PASPARAKIS M, KOLLIAS G, BRUCE ME: Tumor necrosis factor alpha-deficient, but not interleukin-6-deficient, mice resist peripheral infection withscrapie. J. Virol. (2000) 74:3338-3344.
52. MABBOTT NA, BRUCE ME, BOTTO M, WALPORT MJ, PEPYS MB: Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie. Nat. Med. (2001) 7:485-487.
53. KLEIN MA, KAESER PS, SCHWARZ P et al.: Complement facilitates early prion pathogenesis. Nat. Med. (2001) 7:488-492.
54. SCHENK D, BARBOUR R, DUNN W et al.: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 400:173-177.
55. JANUS C, PEARSON J, MCLAURIN J et al.: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2000) 408:979-982.
56. RACE RE, CAUGHEY B, GRAHAM K, ERNST D, CHESEBRO B: Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J. Virol. (1988) 62:2845-2849.
57. BUTLER DA, SCOTT MR, BOCKMAN JM et al.: Scrapie-infected marine neuroblastoma cells produce protease-resistant prion proteins. J. Virol. (1988) 62:1558-1564.
58. NISHIDA N, HARRIS DA, VILETTE D et al.: Successful transmission of three mouse-adapted scrapie strains to marine neuroblastoma cell lines overexpressing wild-type mouse prion protein. J. Virol (2000) 74:320-325.
59. HARRIS DA: Cell biological studies of the prion protein. Curr. Issues Mol. Biol. (1999) 1:65-75.
60. LEHMANN S, HARRIS DA: Mutant and infectious prion proteins display common biochemical properties in cultured cells. J. Biol. Chem. (1996) 271:1633-1637.
61. CHIESA R, HARRIS DA: Nerve growth factor-induced differentiation does not alter the biochemical properties of a mutant prion protein expressed in PC 12 cells. J. Neurochem. (2000) 75:72-80.
62. SCHATZL HM, LASZLO L, HOLTZMAN DM et al.: A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J. Virol. (1997) 71:8821-8831.
63. CAUGHEY B, RACE RE, ERNST D, BUCHMEIER MJ, CHESEBRO B: Prion protein biosynthesis in scrapie-infected and uninfecred neuroblastoma cells. J. Virol. (1989) 63:175-181.
64. RACE RE, CAUGHEY B, GRAHAM K, ERNST D, CHESEBRO B: Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J. Virol. (1988) 62:2845-2849.
65. CAUGHEY B, RAYMOND GJ, ERNST D, RACE RE: N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J. Virol. (1991) 65:597-603.
66. ENARI M, FLECHSIG E, WEISSMANN C: Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc. Natl. Acad. Sci. USA (2001) 98:9295-9299.
67. PERETZ D, WILLIAMSON RA, KANEKO K et al.: Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature (2001) 412:739-743.
68. BOSQUE PJ, PRUSINER SB: Cultured cell sublines highly susceptible to prion infection. J. Virol. (2000) 74:4377-4386.
69. CAUGHEY B, NEARY K, BULLER R et al.: Normal and scrapie-associated forms of prion protein differ in their sensitivities to phospholipase and proteases in intact neuroblastoma cell. J. Virol. (1990) 64:1093-1101.
70. GILCH S, WOPFNER F, RENNER-MULLER I et al.: Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells. J. Biol. Chem. (2003) 278:18524-18531.
71. CAUGHEY B, RAYMOND GJ: The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J. Virol. (1991) 266:18217-18223.
72. Sc and delays onset of prion disease. EMBO J. (2001) 20:3857-3966.
73. KANEKO K, ZULIANELLO L, SCOTT M et al.: Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc. Natl. Acad. Sci. USA (1997) 94:10069-10074.
74. HORIUCHI M, BARON GS, XIONG LW, CAUGHEY B: Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain. J. Biol. Chem. (2001) 276:15489-15497.
75. Sc binding antibodies are potent inhibitors of prion replication in cell lines. J. Biol. Chem. (2004) 279:39671-39676.
76. c degradation. J. Neurochem. (2004) 89:454-463.
77. SOUAN L, MARGALIT R, BRENNER O, COHEN IR, MOR F: Self prion protein peptides are immunogenic in Lewis rats. J. Autoimmun. (2001) 17:303-310.
78. SOUAN L, TAL Y, FELLING Y, COHEN IR, TARABOULOS A, MOR F: Modulation of proteinase-K resistant prion protein by prion peptide immunization. Eur. J. Immunol. (2001) 31:2338-2346.
79. HEPPNER FL, MUSAHL C, ARRIGHI I et al.: Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science (2001) 294:178-182.
80. SCHWARZ A, KRÄTKE O, BURWINKEL M et al.: Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci. Lett. (2003) 350:187-189.
81. SIGURDSSON EM, BROWN DR, DANIELS M et al.: Immunization delays the onset of prion disease in mice. Am. J. Pathol. (2002) 161:13-17.
82. SIGURDSSON EM, SY M, LI R et al.: Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett. (2003) 336:185-187.
83. WHITE AR, ENEVER P, TAYEBI M et al.: Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature (2003) 422:80-83.
84. TAL Y, SOUAN L, COHEN-SOLAL M et al.: Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice. J. Neurosci. Res. (2003) 71:286-290.
85. POLYMENIDOU M, HEPPNER F, PELLICIOLI EC et al.: Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc. Natl. Acad. Sci. USA (2004) 101(Suppl. 2):14670-14676.
86. BANSAL-PAKALA P. JEMBER AG, CROFT M: Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat. Med. (2001) 7:907-912.
87. MALUCCI G, DICKINSON A, LINEHAN M et al.: Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science (2003) 302:871-874.
88. TELLING GC, SCOTT M, MASTRIANNI J et al.: Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell (1995) 83:79-90.
89. SOLFOROSI L, CRIADO JR, MCGAVERN DB et al.: Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science (2004) 303:1514-1516.
90. KORTH C, STIERLI B, STREIT P et al.: Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature (1997) 390:74-77.
91. FISCHER MB, ROECKL C, PARIZEK P, SCHWARZ HP, AGUZZI A: Binding of disease-associated prion protein to plasminogen. Nature (2000) 408:479-483.
92. MORONCINI G, KANU N, SOLFOROSI L: Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. Proc. Natl. Acad. Sci. USA (2004) 101:10404-10409.
93. PARAMITHIOTIS E, PINARD M, LAWTON T et al.: A prion protein epitope selective for the pathologically misfolded conformation. Nat. Med. (2003) 9:893-899.
94. ZOU WQ, CASHMAN NR: Acidic pH and detergents enhance in vitro conversion of human brain PrPC to a PrPSc-like form. J. Biol. Chem. (2002) 277:43942-43947.
95. LEHTO MT, ASHMAN DA, CASHMAN NR: Treatment of ScN2a cells with prion-specific YYR antibodies Proceedings of the first International Conference of the Network of Excellence: Neuroprion. (24-28 May 2004) Paris, France.
96. MCLAURIN J, CECAL R, KIERSTEAD ME et al.: Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. (2002) 8:1263-1269.